GSK takes advantage of natural experiment to study whether shingles vaccine can reduce dementia risk
After multiple studies have suggested a link between its shingles vaccine and dementia prevention, GSK is taking advantage of ...
Prominent outside scientists who help the NIH evaluate its internal research programs are being abruptly removed ...
The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...
GSK partners with UK research groups to study if Shingrix shingles vaccine reduces dementia risk, analyzing NHS data from ...
GlaxoSmithKline is investing in artificial ... where he was responsible for establishing new areas of research focus including the concepts of druggability and network pharmacology.
Zacks Investment Research on MSN6d
GSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold?GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also ...
GSK Plc is studying a large group of elderly adults in the UK to determine if its blockbuster shingles vaccine reduces the risk of dementia, potentially opening the door to an expanded label for the ...
Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback